Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 5/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16836777 | 0.89 | PTGER4 (0.45) | PTGER4CYP4F2CYP4A11TACR1FFAR1 | |
| SCHEMBL16836854 | 0.79 | PTGER4 (0.51) | PTGER4TACR1NPC1ALDH1A1MAPT | |
| SCHEMBL20306778 | 0.79 | PTGER4 (0.45) | PTGER4 | |
| SCHEMBL1166673 | 0.76 | GSK3B (0.42) | FFAR1 | |
| SCHEMBL3426549 | 0.76 | AGXT (0.41) | MRGPRX4FFAR1 | |
| SCHEMBL3398564 | 0.75 | CHRM3 (0.41) | PTGER4TACR1MRGPRX4FFAR1NPC1 | |
| SCHEMBL4730225 | 0.74 | ATR (0.46) | — | |
| SCHEMBL5341608 | 0.74 | MRGPRX4 (0.52) | MRGPRX4ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL1362409 | 0.73 | LMNA (0.41) | MRGPRX4FFAR1ALDH1A1 | |
| SCHEMBL4783563 | 0.73 | PRKCI (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005721-B2 | Dimethylbenzoic acid compounds | ELI LILLY AND COMPANY (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005721-B2 | Dimethylbenzoic acid compounds | ELI LILLY AND COMPANY (US) | 2018-06-26 | — | — | US | disclosed |
| EP-3083554-A1 | DIMETHYLBENZOIC ACID COMPOUNDS | Eli Lilly & Company (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20160251306-A1 | DIMETHYLBENZOIC ACID COMPOUNDS | ELI LILLY AND COMPANY | 2016-09-01 | — | — | US | disclosed |
| US-20160251306-A1 | DIMETHYLBENZOIC ACID COMPOUNDS | ELI LILLY AND COMPANY | 2016-09-01 | — | — | US | disclosed |
| US-20160251306-A1 | DIMETHYLBENZOIC ACID COMPOUNDS | ELI LILLY AND COMPANY | 2016-09-01 | — | — | US | disclosed |
| WO-2015094912-A1 | DIMETHYLBENZOIC ACID COMPOUNDS | ELI LILLY AND COMPANY (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015094912-A1 | DIMETHYLBENZOIC ACID COMPOUNDS | ELI LILLY AND COMPANY (US) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005721-B2 | Dimethylbenzoic acid compounds | PTGER4, EDNRB, EPB41 | PTGER4 1/4885CYP4F2 866/4885CYP4A11 112/4885 |
| US-20160251306-A1 | DIMETHYLBENZOIC ACID COMPOUNDS | PTGER4, EDNRB, EPB41 | PTGER4 1/4885CYP4F2 866/4885CYP4A11 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.